Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.
AUTOR(ES)
Kaul, S
RESUMO
Stavudine was administered (15 mg/kg of body weight) intravenously and orally to two monkeys in a randomized crossover study. Plasma and urine samples were analyzed for stavudine by high-performance liquid chromatography, and pharmacokinetic parameters were derived by a noncompartmental method. Total body clearance of stavudine was 0.64 liters/h/kg, with a steady-state volume of distribution of 0.68 liters/kg, a terminal half-life of 0.83 h, a urinary recovery of 44%, and an oral bioavailability of 80%. These values were reasonably similar to those reported for patients with AIDS or AIDS-related complex.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=187922Documentos Relacionados
- Novel 4′-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity
- Potentiation of the stavudine anti-human immunodeficiency virus activity by 5-fluorouracil.
- 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
- In Vivo Toxicity, Pharmacokinetics, and Anti-Human Immunodeficiency Virus Activity of Stavudine-5′-(p-Bromophenyl Methoxyalaninyl Phosphate) (Stampidine) in Mice
- Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.